AIFF vs LNTH vs VREX Stock Comparison

Firefly Neuroscience, Lantheus Holdings and Varex Imaging Prices as of Oct 26, 2026 Peers: Industry group
LNTH Lantheus Holdings, Inc.
$99.92 +0.2% 1M +78.2% 1Y
Market cap
$6.52B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
10 wins
VREX Varex Imaging Corp
$18.41 -0.2% 1M +53.5% 1Y
Market cap
$776.53M
P/E
35.1x
Revenue (TTM)
$865.00M
Div. yield
–
Diagnostic Equipment Healthcare

Head to Head

11 decided of 12

Lantheus Holdings leads on 10 of the 12 questions below (Lantheus Holdings 10, Firefly Neuroscience 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAIFFLNTHVREXLeader
Larger companyMarket capitalisation $20.57M $6.52B $776.53M LNTH
Cheaper on earningsLower P/E, profitable companies only -2.2x 23.7x 35.1x LNTH
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 17.3x 21.2x LNTH
Faster revenue growthRevenue growth, trailing twelve months +320.3% +2.3% +5.3% AIFF
More profitableNet margin, trailing twelve months -524.5% 17.7% 2.6% LNTH
Better return on capitalReturn on invested capital — 12.5% 6.9% LNTH
Less leveragedLower net debt / EBITDA — -0.1x 2.5x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -54.8% +78.2% +53.5% LNTH
Better 5-year returnAnnualised price return, 5 years -61.1%/yr +34.7%/yr -7.0%/yr LNTH
Less volatileAnnualised volatility, 1 year 160.0% 32.4% 57.6% LNTH
Higher overall scoreMean of the five percentile scores vs peers 38/100 80/100 51/100 LNTH

Percentile Scorecard

AIFFLNTHVREX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAIFFLNTHVREX
Valuation 15 #194 of 228 81 #45 of 228 87 #31 of 228
Growth 61 #87 of 221 63 #83 of 221 23 #170 of 221
Profitability 14 #179 of 208 94 #13 of 208 66 #71 of 208
Financial Health 79 #52 of 239 69 #74 of 239 41 #141 of 239
Shareholder Returns 20 #110 of 137 93 #11 of 137 36 #88 of 137
Overall 38 80 51
  • AIFF ranked among 248 companies in Medical Devices and Diagnostics
  • LNTH ranked among 248 companies in Medical Devices and Diagnostics
  • VREX ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAIFFLNTHVREXSPY
1 month -53.2%+0.2%-0.2% -0.8%
3 months -20.3%-7.5%+67.7% +3.5%
6 months -55.7%+18.8%+44.8% +7.0%
Year to date +6.8%+50.1%+58.0% +12.2%
1 year -54.8%+78.2%+53.5% +13.0%
3 years -83.7%+49.5%+6.4% +86.3%
3 years, per year -45.4%+14.4%+2.1% +23.1%
5 years -99.1%+343.3%-30.3% +68.6%
5 years, per year -61.1%+34.7%-7.0% +11.0%
10 years -79.1%+1,048.5%— +258.0%
10 years, per year -14.5%+27.7%— +13.6%

Risk

MeasureAIFFLNTHVREXSPY
Volatility, 1Y 160.0%32.4%57.6% 12.7%
Downside volatility, 1Y 109.1%27.5%50.0% 12.7%
Beta vs S&P 500, 1Y 1.500.591.11 1.00
Return / volatility, 1Y -0.342.420.93 1.02
Max drawdown, 5Y -99.6%-59.5%-78.8% -25.4%
From 52-week high -68.9%-9.9%-0.9% -1.8%
52-week high $3.02$110.94$18.58 $779.14
52-week low $0.64$50.69$9.32 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAIFFLNTHVREX
P/E now vs peer median -2.0xmedian 30.6x 23.6xmedian 30.6x 35.1xmedian 30.6x
P/S now vs peer median 10.8xmedian 3.0x 4.2xmedian 3.0x 0.9xmedian 3.0x
EV/EBITDA now vs peer median -1.1xmedian 17.5x 16.4xmedian 17.5x 10.1xmedian 17.5x
P/FCF now vs peer median -2.7xmedian 23.3x 16.8xmedian 23.3x -38.4xmedian 23.3x
P/B now vs peer median 1.3xmedian 2.4x 5.0xmedian 2.4x 1.5xmedian 2.4x
PEG now vs peer median -0.03median 0.87 0.22median 0.87 -9.15median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAIFFLNTHVREX
Revenue $1.80M $1.56B $865.00M
Gross profit $802.00K $936.02M $296.90M
Operating income -$9.14M $302.34M $72.20M
Net income -$9.11M $275.31M $22.40M
Free cash flow -$7.20M $387.83M -$20.20M
R&D $1.78M $173.09M $91.40M
EPS (diluted) $-0.70 $4.08 $0.52
Cash & equivalents $9.23M $593.30M $99.20M
Total debt – $571.05M $347.10M
Shares (diluted) 13.50M 67.52M 42.60M
Enterprise value $1.15M $4.69B $308.33M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAIFFLNTHVREX
P/E -2.0x 23.6x 35.1x
P/FCF -2.7x 16.8x -38.4x
P/Operating cash flow -2.8x 15.8x 68.7x
P/S 10.8x 4.2x 0.9x
P/B 1.3x 5.0x 1.5x
P/Tangible book 1.4x 10.5x 1.6x
EV/EBITDA -1.1x 16.4x 10.1x
EV/EBIT -1.1x 21.5x 14.2x
EV/Revenue 5.6x 4.2x 1.2x
EV/FCF -1.4x 16.8x -50.7x
EV/Operating cash flow -1.4x 15.7x 90.6x
PEG (3Y EPS CAGR) -0.03 0.22 -9.15

Growth

14 metrics
MetricAIFFLNTHVREX
Revenue growth (1Y) 320.3% 2.3% 5.3%
Revenue CAGR (3Y) -40.3% 11.4% -1.2%
Gross profit growth (1Y) 99.0% -3.4% 6.1%
Gross profit CAGR (3Y) -32.6% 16.3% 1.2%
Operating income growth (1Y) 19.8% -30.9% 297.8%
Operating income CAGR (3Y) -52.0% 118.8% -2.3%
Net income growth (1Y) 60.1% 1.6% 116.7%
Net income CAGR (3Y) 15.8% 102.1% -9.2%
EPS growth (1Y) 81.8% 5.8% 116.1%
EPS CAGR (3Y) 69.0% 105.5% -3.8%
Operating cash flow growth (1Y) 19.1% -21.7% -81.1%
Operating cash flow CAGR (3Y) -8.4% 14.5% -47.6%
Free cash flow growth (1Y) 17.6% -10.1% -155.5%
Free cash flow CAGR (3Y) -6.3% 103.0% -33.5%

Profitability

14 metrics
MetricAIFFLNTHVREX
Gross margin 44.6% 60.1% 34.3%
EBITDA margin -496.9% 25.4% 11.7%
Operating margin -508.1% 19.4% 8.3%
Pretax margin -506.2% 23.3% 3.2%
Net margin -524.5% 17.7% 2.6%
FCF margin -400.2% 24.9% -2.3%
Operating cash flow margin -388.6% 26.5% 1.3%
Return on equity -78.8% 21.8% 4.5%
Return on assets -65.8% 11.6% 2.1%
Return on invested capital – 12.5% 6.9%
Return on capital employed -77.9% 14.8% 8.0%
Asset turnover 0.1x 0.7x 0.8x
Cash conversion (OCF / net income) 0.8x 1.5x 0.5x
Stock comp / revenue 36.4% 5.0% 1.7%

Financial Health

11 metrics
MetricAIFFLNTHVREX
Debt / assets – 23.6% 31.6%
Debt / equity – 0.4x 0.7x
Net debt / EBITDA – -0.1x 2.5x
Debt / FCF – 1.5x -17.2x
Liabilities / assets 12.6% 45.7% 53.6%
Equity / assets 87.4% 54.3% 46.4%
Interest coverage – 15.3x 1.9x
Current ratio 4.9x 3.1x 3.4x
Quick ratio 4.5x 2.8x 1.3x
Cash ratio 4.4x 1.8x 0.5x
Altman Z-score -5.24 5.46 2.28

Shareholder Returns

7 metrics
MetricAIFFLNTHVREX
Dividend yield – – –
Net buyback yield -2.1% 2.9% -0.4%
Shareholder yield -2.1% 2.9% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAIFFLNTHVREX
Forward P/E – 17.3xFY2026 21.2xFY2026
EPS, next fiscal year – $5.76FY2026 $0.87FY2026
EPS growth, next FY – -5.3%FY2026 -3.3%FY2026
EPS growth, the year after – +4.2% +14.9%
Revenue, next fiscal year – $1.57BFY2026 $829.68MFY2026
Revenue growth, next FY – +1.8%FY2026 -1.8%FY2026
Revenue growth, the year after – +12.7% +2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAIFFLNTHVREX
Held by institutions 7.9% 100.0% 95.2%
Institutions holding 23 465 186
Change in shares held, QoQ +34.3% +3.4% -2.7%
Institutions buying 10 248 98
Institutions selling 6 142 58
Buyers to sellers 1.67 1.75 1.69

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AIFFLNTHVREX
AIFF 1.00 0.04 0.07
LNTH 0.04 1.00 0.15
VREX 0.07 0.15 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AIFF, LNTH and VREX?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Firefly Neuroscience (AIFF) $20.57M, Lantheus Holdings (LNTH) $6.52B, Varex Imaging (VREX) $776.53M.

Which stock is cheaper, AIFF, LNTH and VREX?

Lantheus Holdings (LNTH) trades on the lowest price-to-earnings ratio (Firefly Neuroscience (AIFF) -2.2x, Lantheus Holdings (LNTH) 23.7x, Varex Imaging (VREX) 35.1x). On next year's consensus earnings, Lantheus Holdings (LNTH) is cheapest (Lantheus Holdings (LNTH) 17.3x, Varex Imaging (VREX) 21.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Firefly Neuroscience (AIFF) grew revenue fastest over the trailing twelve months: Firefly Neuroscience (AIFF) +320.3%, Lantheus Holdings (LNTH) +2.3%, Varex Imaging (VREX) +5.3%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Firefly Neuroscience (AIFF) -524.5%, Lantheus Holdings (LNTH) 17.7%, Varex Imaging (VREX) 2.6%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.5%, Varex Imaging (VREX) 6.9%).

Which stock has performed better?

Over the past year Lantheus Holdings (LNTH) returned the most: Firefly Neuroscience (AIFF) -54.8%, Lantheus Holdings (LNTH) +78.2%, Varex Imaging (VREX) +53.5%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Firefly Neuroscience (AIFF) -61.1%/yr, Lantheus Holdings (LNTH) +34.7%/yr, Varex Imaging (VREX) -7.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Firefly Neuroscience (AIFF) 160.0%, Lantheus Holdings (LNTH) 32.4%, Varex Imaging (VREX) 57.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AIFF, LNTH and VREX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 10. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.